The Law Offices of Frank R. Cruz continues its investigation of Scynexis, Inc. (“Scynexis” or the “Company”) (NASDAQ: SCYX) on behalf of investors concerning the Company’s possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On September 25, 2023, Scynexis disclosed that it would be recalling ibrexafungerp tablets from the market and placing a temporary hold on clinical studies of ibrexafungerp due to a recent review finding that “a non-antibacterial beta-lactam drug substance is manufactured using equipment common to the manufacturing process for ibrexafungerp,” which has the potential “to act as sensitizing agents that may trigger hypersensitivity or an allergic reaction in some people.”

On this news, Scynexis’s stock price fell $1.13, or 34.1%, to close at $2.18 per share on September 25, 2023, thereby injuring investors.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased Scynexis securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230927664234/en/